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Background: Immediate breast reconstruction with an expander is a reasonable option for properly selected
patients. After reconstruction, patients have severe postoperative pain, which responds poorly to opioids. Our aim
was to evaluate if continuous wound infusion of a local anaesthetic into the surgical wound reduces postoperative
pain, consumption of opioids and incidence of chronic pain compared to standard intravenous piritramide after
primary breast reconstruction in breast carcinoma patients.
Methods: Altogether, 60 patients were enrolled in our study; one half in the group with wound infusion of a local
anaesthetic, and the other half in the standard (piritramide) group. Parameters measured included: pain intensity
(visual analogue scale), drug requirements, alertness, hospitalisation, side-effects and late complications. A p-value
of < 0.05 was considered statistically significant.
Results: In the recovery room, the test group reported less acute pain at rest (P = 0.03) and at activity (P = 0.01),
and on the day of the surgical procedure they reported less pain at activity (P = 0.003). Consumption of piritramide
and metoclopramide was lower in this group (P < 0.0001), but their alertness after the surgical procedure was
higher compared to the standard group (P < 0.001). After three months, the test group reported less chronic pain
(P = 0.01).
Conclusions: After primary tissue expander breast reconstruction, wound infusion of a local anaesthetic
significantly reduces acute pain and enables reduced opioid consumption, resulting in less postoperative sedation
and reduced need for antiemetic drugs. Wound infusion of a local anaesthetic reduces chronic pain.
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Breast cancer is the most common cancer in women
both in the developed and the developing countries [1].
Although systemic therapy and conservative surgery are
recommended treatments, mastectomy is still the stand-
ard surgical procedure for the local treatment of all
stages of breast cancer [2]. In the United States, one
third of newly discovered breast cancer patients decide
to undergo a mastectomy, mostly because of fear of re-
currence. For those women who choose mastectomy as
part of their approach to breast-cancer therapy or pre-
vention, reconstruction may be offered as an option [3].
In Breast Center Humanitas in Milan, breast reconstruc-
tion after mastectomy was performed in 82% of patients
in 2010 [4].
As a reconstruction method, an expander or an im-
plant provides a reasonable option in properly selected
patients. Patients with small, minimally ptotic breasts
are good candidates. The advantages of this method are
simple operation, no morbidity at a distant donor site,
use of tissue of similar colour, texture and sensation, re-
duced operating time, and faster postoperative recovery
[5]. Although breast reconstruction with a tissue ex-
pander is simple, it causes severe postoperative pain that
may respond poorly to opioids [6]. Severe postoperative
pain after breast implant insertion is well-known from
breast augmentation studies [7]. Pain relief was poor
despite the progressive increase in the opioid dose and
presence of adverse effects of opioids [6].
Use of local anaesthetics is one of the possible
methods for the treatment of acute postoperative pain.
To our knowledge, only three studies have been pub-
lished on the use of local anaesthetics for the treatment
of acute postoperative pain after breast reconstruction
[8-10]. Use of local anaesthetics administered into the
surgical wound has been shown to be an effective treat-
ment for postoperative pain control and decreased opi-
oid consumption. However, only a small number of
patients were included in these studies. Only one of the
studies was prospective and randomized [8] but it was
performed on patients with delayed breast reconstruc-
tion after mastectomy. We failed to find any prospective
randomized trial on the use of local anaesthetics for the
treatment of postoperative pain after primary breast re-
construction with a tissue expander.
We decided to conduct study because of the good re-
sults obtained in previous studies on axillary lymph node
dissection and mastectomy due to breast carcinoma
[11-14]. Levobupivacaine and ropivacaine are long-lasting
and very effective local anaesthetics with a favourable
toxic profile [15]. Levobupivacaine was chosen for use in
our patients because it was available on our market at the
time of our study, while ropivacaine was not. The duration
of action of local anaesthetic is proportional to the lengthof time that it is in contact with the nerve [16]. Pacik
found that a continuous flow as well as intermittent
bolus anaesthesia was effective in controlling postoper-
ative pain in augmentation mammoplasty [17]. But
according to Talbot et al., a bolus application of local
anaesthetic was not a successful pain treatment after
mastectomy [18], so we decided to use a continuous in-
fusion of local anaesthetic. The aim of our prospective
randomized study was to evaluate the effectiveness of a
local anaesthetic administered into the surgical wound
as a continuous infusion after immediate breast recon-
struction with a tissue expander. Our hypothesis was
that local anaesthetics are more effective than standard
intravenous analgesics for pain relief. We also wanted
to determine that continuous infusion of the local an-
aesthetic enables lower consumption of opioids, redu-
cing the need for antiemetic drugs and sedation
compared to standard opioid-based analgesia.
Methods
Altogether, 60 breast carcinoma patients were enrolled
in the study protocol between January 2011 and May
2012: 72 patients who were eligible for inclusion were
offered the opportunity to participate in our study dur-
ing the recruitment period; 12 of them declined partici-
pation, and the remaining 60 were included in the study.
Patients listed for mastectomy and primary reconstruc-
tion with a tissue expander because of the presence of
breast carcinoma or for prophylactic mastectomy, were
randomized during the routine preoperative anaesthetic
assessment. Anaesthesia for the procedure was the same
for all study subjects. We used the same protocol as
already reported for patients with axillary dissection
[14]. The first study arm was treated with continuous
local analgesia, and the other (control) arm received
standard intravenous analgesia. Allergies to local anaes-
thetics and chronic pre-operative opioid consumption
were the criteria to exclude patients from our study.
After informed consent was obtained the randomization
was made by research nurses from the Clinical Research
Unit of the Institute of Oncology Ljubljana. The research
nurse performed randomization using random numbers
generated by a computer and then informed the principal
investigator about the treatment allocation of the patient.
Surgical procedures were performed by ten experi-
enced oncology surgeons and ten plastic surgeons. Senti-
nel lymph node biopsy was performed in 55 patients. In
one patient with positive imprint cytology of the sentinel
lymph node, axillary lymphadenectomy was performed
immediately.
The study was reviewed by the The National Medical
Ethics Committee of the Republic of Slovenia and per-
formed in accordance with the ethical standards laid
down in the appropriate version of the 1964 Declaration
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Review Board of the Institute of Oncology Ljubljana and
conducted with the understanding and consent of all
subjects involved. Study was entirely financed by the In-
stitute of Oncology as a part of public service.
Test group of patients
Before wound closure, a fenestrated wound catheter was
placed by a plastic surgeon into the wound cavity under
the musculus pectoralis major and upon the entire length
over the upper side of the wound. The wound catheter
was fenestrated along 15 cm in the distal part. Nine
patients undergoing bilateral reconstruction received a
catheter into the wound on both sides. A bolus of 15 mL
of 0.25% levobupivacaine was injected into the wound
through the catheter immediately after wound closure.
Surgical drains and the fenestrated catheter were
clamped for 5 minutes after the administration of levo-
bupivacaine to enable its absorption. After the administra-
tion of the bolus, the elastomeric pump was connected to
the wound catheter. Clamps on the surgical drains were
released after 5 minutes, and the clamp on the fenestrated
catheter was released after 20 minutes, enabling a con-
tinuous infusion of 0.25% levobupivacaine. The elasto-
meric pump contained 100 mL of 0.25% levobupivacaine,
and the flow rate was 2 mL per h. The catheter was re-
moved after 50 h.
Control group of patients
The control patients, that is, those who received the
standard intravenous piritramide treatment, were on a
continuous intravenous infusion with piritramide (30 mg),
metoclopramide (20 mg) and metamizole (2.5 g) in
100 mL of 0.9% sodium chloride (3 mL/h - 6 mL/h) until
the next morning. The nursing staff were instructed to
maintain the lowest drip rate of infusion, which relieved
the pain. Our experience is that after the first postopera-
tive day the severity of pain decreases and becomes bear-
able. In order to avoid the side effects of opioids the
patients from our control group were treated with con-
tinuous intravenous infusion only during the first 24 h as
is the standard of care in our department.
Both groups of patients
Patient-controlled analgesia was not used in our patients.
A rescue dose of analgesics was administered by nursing
stuff on the demand of a patient. Whenever needed, pa-
tients from both groups could get an intravenous bolus of
a rescue analgesic (3 mg of piritramide) and/or an anti-
emetic drug. In the case of nausea or vomiting, the patient
received a bolus of an antiemetic drug, the first one being
metoclopramide. If no relief was achieved, 1 mg of grani-
setron or, with persistent nausea 1.25 mg of droperidol,
was administered intravenously.From the first postoperative day, all patients received
analgesics in the form of tablets. They were administered
one tablet of 100 mg of diclofenac and a combination of
paracetamol 2,600 mg per day and tramadol 300 mg
per day. The consumption of drugs (analgesia infusion,
intravenous drugs and tablets) during hospitalisation
was registered.
Pain measurement
Data about pain (visual analogue scale (VAS) score) were
collected by nursing staff, that is, by an independent ob-
server. Pain was measured using the standard VAS score,
ranging from 0 to 10. The first measurement was made
in the recovery room. Pain was also measured 3, 6 and
9 h after the surgical procedure. Thereafter, pain was
measured every 8 h over the next 4 days. All VAS mea-
surements were performed twice, at rest and on activity
of an upper extremity. Median VAS score was calculated
on the day of surgery and on the first postoperative day
from all eight and six measurements, respectively.
Three months after the surgical procedure, that is, be-
fore the tissue expander was replaced by an implant,
the patients were asked about pain in the postoperative
area or upper extremities. Chronic pain after 3 months
was defined as pain that bothered patients during nor-
mal daytime activities or during rest or sleep. In the ma-
jority of patients with persistent pain it occurred during
movement of an upper extremity or in a specific position
of the extremity. Pain was permanently present when at
rest in only a minority of patients. Six hours after the
surgical procedure, we measured patients' alertness
using the observer’s assessment of alertness/sedation
(OAA/S) scale [19] in a composite way, as we did in our
previous study [14].
After the surgical procedure, the patients received
adjuvant therapy according to the tumour stage and
guidelines. Adjuvant chemotherapy, external irradiation
and/or hormone therapy was used in 38%, 20% and/or
60% of the patients, respectively. The occurrence of
complications (inflammation, haematoma and other)
was recorded.
Statistical analysis
In order to estimate the probability (power) to reject the
null hypothesis, PS: Power and Sample Size Calculations
Software (Version 3.0, January 2009) was used. Prior
data indicated that the failure rate among controls was
0.5. If the true failure rate for experimental subjects is
0.15, 27 experimental subjects and 27 control subjects
are needed to be able to reject the null hypothesis that
the failure rates for experimental and control subjects
are equal, with probability (power) of 0.8. The type-I
error probability associated with this test of the null
hypothesis is 0.05.
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used according to data distribution. The association be-
tween categorical variables was tested by the chi-square test
or Fisher's exact test, as appropriate. All comparisons were
two-sided and a P-value <0.05 was considered statistically
significant. The statistical packages PASW 18 (SPSS Inc.,
Chicago, IL, USA) and R 2.11.1 (R Foundation for Statistical
Computing, Vienna, Austria) were used for the analysis.
Results
The mean age of patients was 47.8 years (range 25 to
64 y), height was 166 cm (range 153 to 178 cm), weight
was 61.7 kg (range 45 to 85 kg), and the body mass
index (BMI) was 22.4 (range 17 to 31.2). There were no
significant differences between the study groups in BMI,
American Society of Anesthesiology (ASA) score, co-
morbidities (Table 1), type and length of surgical proced-
ure, extent of lymph node dissection, adjuvant therapy,
complications, or hospital stay (Table 2).
Acute pain
Data on postoperative pain are presented in Table 3.
Opioid consumption
Consumption of piritramide during the first 24 h after the
surgical procedure was lower in the test group compared
to the control group (P <0.0001) (Table 4). Alertness, as
measured 6 h after the surgical procedure, was higher in
the test group compared to the control group (P <0.001).
Nausea
Patients in the test group reported less nausea than pa-
tients in the standard group. Consumption of metoclopra-
mide during the first 24 h after the surgical procedure was
also lower in the test group compared to the standard
group (P <0.0001).
Complications
No local signs of an infection were observed in the area
where the wound catheter was inserted. All microbiological
samples taken were negative. There were no significant dif-
ferences in the complications following the surgical pro-
cedure between the two groups. Altogether, two patients
(3.3%) underwent another surgical procedure because of
haematoma, one from the test group and one from the
standard group. Inflammation after the surgical procedure
occurred in four patients, one in the test group and three
in the standard group. After antibiotic therapy, all patients
recovered, and the tissue expander stayed in place.
Hospital stay
The average postoperative hospital stay was 5.3 days.
There was no significant difference in the duration of
the hospital stay between the two groups.Unilateral and bilateral tissue expander
In order to collect a sufficient number of patients all
cases with a unilateral or bilateral tissue expander were
included in our study. As a result of randomization the
number of the patients with a bilateral and unilateral tis-
sue expander reconstruction in the local anaesthetic and
control group was nine and ten, respectively. Patients
with bilateral tissue expander reconstruction received
2 mL/hour of 0.25% levobupivacaine on each side. Thus,
the total daily amount of levobupivacaine was 240 mg,
which is within the recommended range and does not
exceed the maximum tolerated dose. Patients from the
control group with a bilateral reconstruction had more
severe pain than patients with a unilateral reconstruc-
tion, whereas pain in the local anaesthetic group was not
different after a bilateral or unilateral reconstruction. In
the control group the mean VAS score in the recovery
room after a bilateral and unilateral reconstruction was
6.45 and 4.09, whereas on the day of surgery it was 5.36
and 3.13, respectively (P <0.05).
Late complications (three months after primary
reconstruction)
Three months after primary reconstruction, the patients
completed a questionnaire on pain. In the test and the
control groups of patients, pain was reported in 16.7%
and 50% (P = 0.01), respectively. Unilateral lymphoedema
of the arm was present in two patients, one from the
control group and one from the test group. The patient
with oedema from the test group underwent a dissection
of the axilla; the patient from the control group under-
went a bilateral sentinel lymph node biopsy.
Discussion
Ideally the study should have been placebo double-blinded
to eliminate all biases. However, the cost of the elasto-
meric pump and wound catheter was 175 euro, so we
were not able to perform a double-blind study. However,
the cost of an elastomeric pump and wound catheter was
not the only reason that precluded us from performing
such a study. We had also ethical reasons for not carrying
out a placebo-controlled study. Namely, a reconstruction
with a tissue expander is a very painful procedure for the
majority of patients, so we felt that it is not ethical to have
a control group treated by placebo only. Instead, we of-
fered our control group of patients the best available treat-
ment, that is, intravenous analgesia. Based on the good
results of our preliminary data on the use of continuous
local anaesthetics for treatment of pain, our patients were
willing to participate in our study because they were of-
fered state-of-the-art pain treatment versus potentially
even more effective pain treatment.
Sub-pectoral breast augmentation and breast recon-
struction with an expander or an implant are associated
Table 1 Patient characteristics
Characteristic Sub-group Local anaesthetic group Standard group P-value
Number of patients 30 30 -
Age, years, mean 47.6 48.0 0.88
Height, m, mean 1.66 1.66 0.78
Weight, kg, mean 60.9 62.5 0.56
Body mass index, kg/m2, mean 22.2 22.6 0.61
ASA score 1 10 15 0. 44
2 19 14
3 1 1
Associated diseases, n 15 14 1.0
Smoker, n 9 10 0.93
Diabetes mellitus, n 0 0 -
Fibromyalgia, n 0 0 -
Rheumatoid arthritis, n 0 0 -
Depression, n 3 1 0.61
Mastectomy side Left n 7 15 0.10
Right n 15 10
Both n 8 5
Tumour diameter, cm, mean (range) 1.2 (0 to 5) 1.3 (0 to 6.5) 0.76
Histology (n = 60) Invasive ductal carcinoma, n 22 17 0.56
Invasive lobular carcinoma, n 2 2
Ductal in situ, n 1 2
Without carcinoma, n 5 9
Grade (n = 58) Grade 0, n 5 9 0.66
Grade I, n 2 1
Grade II, n 11 9
Grade III, n 11 10
Metastatic lymph nodes, median (range) 0 (0 to 21) 0 (0 to 18) 0.98
Resected lymph nodes, median (range) 2 (0 to 33) 3 (0 to 27) 0.97
Hormone receptor-positive n 18 20 0.79
HER-2-positive n 5 7 0.75
ASA, American Society of Anesthesiology; HER-2, human epidermal growth factor receptor-2; n, number of patients.
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[6,9,10,20-24]. Legeby et al. [6] found that pain in the
first 3 h after immediate breast reconstruction with a tis-
sue expander was more severe than pain after mastec-
tomy or axillary dissection. The mean VAS value for
pain in the first 3 h after breast reconstruction was
4.9 and 5.0, if axillary dissection was also performed,
whereas the values were 2.1 for mastectomy and 3.0
for mastectomy with axillary dissection [6]. Similarly,
after tissue-expander implantation, our standard anal-
gesia group of patients also suffered pain in the recovery
room, which was by about 3.0 VAS units larger than in
patients who underwent breast surgery with axillary dis-
section without reconstruction, as reported by Strazisaret al. [14]. The mean VAS score after immediate recon-
struction was 4.9 in the standard analgesia group,
whereas it was only 3.4 in the local anaesthetic group.
In our previous study, the mean VAS score in recovery
after breast cancer surgery with axillary dissection was
2.0 in the standard control group and 0.5 in the local
anaesthetic group [14]. In both our studies, the local
anaesthetic reduced pain by 1.5 VAS units more than
standard treatment alone.
The most positive result of our study is the observa-
tion that 77% of patients treated with local anaesthetics
did not experience severe pain. To our knowledge, there
are no reports in the literature about similarly effective
early postoperative analgesia after the implantation of a
Table 2 Treatment of patients, adjuvant therapy, hospital stay and complications
Sub-group Local anaesthetic group Standard group P-value
Breast surgical procedure (n = 73) Mastectomy; one-sided 23 24 0.58
Mastectomy; two-sided 7 6
Lymph node surgical procedure Axillary lymphadenectomy 6 5 1.00
Sentinel lymph node biopsy; one sided 21 22 1.00
Sentinel lymph node biopsy; two-sided 3 3
Without sentinel 6 5
Reconstruction Expander; one-sided 21 20 1.00
Expander; two-sided 9 10
Median duration of surgical procedure, minutes 140 120 0.62
Neoadjuvant chemotherapy Yes 4 3 1.00
No 26 27
Postoperative chemotherapy Yes 13 10 0.60
No 17 20
Postoperative radiotherapy Yes 9 3 0.11
No 21 27
Hormone therapy Yes 17 19 0.79
No 13 11
Hospitalisation, days 5.2 5.4 0.61
Haematoma 2 1 1.00
Revision 1 1 1.00
Inflammation 1 3 0.61
Values are numbers of patients unless stated otherwise.
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48% of patients treated with local anaesthetics experi-
enced unacceptably severe pain (VAS 4.7 to 10.0) in the
early postoperative period [6]. Legeby et al. used an epi-
dural catheter with only a few holes at its tip andTable 3 Pain in the local anaesthetic group and the standard
Pain assessment time point
In recovery room At rest
On activ
3 h after operation At rest
On activ
6 h after operation at rest
On activ
9 h after operation At rest
On activ
Day of surgery At rest
On activ
First postoperative day At rest
On activ
3 months postoperative (number of patients still having pain)
Data are presented as median visual analogue scale (VAS) score unless stated otherinstilled local anaesthetic every 3 h. They probably did
not establish an equal distribution of the local anaes-
thetic along the entire length of the muscle and the
wound. On the other hand, we used quality wound-
catheters that were perforated 15 cm at the distal end,group of patients
Local anaesthetic group Standard group P-value
3.0 4.0 0.03
ity 3.0 5.0 0.01
1.0 1.5 0.45
ity 3.0 5.0 0.04
2.0 2.0 0.58
ity 3.0 5.0 0.009
1.0 2.0 0.28
ity 4.0 5.0 0.01
1.9 2.1 0.23
ity 3.8 4.8 0.003
1.5 1.7 0.69
ity 4.0 3.7 0.96
5 15 0.01
wise.
Table 4 Mean consumption of drugs, and alertness, in the local anaesthetic group and the control group of patients
Pain Local anaesthetic group Standard group P-value
Opioid (piritramide) consumption during the first 24 h, mg, mean 9.8 29.4 <0.0001
Metamizole consumption during the first 24 h, g, mean 2.8 4.5 <0.0001
Metoclopramide consumption during the first 24 h, mg, mean 11.0 24.3 <0.0001
Tramadol/paracetamol consumption during the first four days, number of tablets, mean 16.8 18.8 0.46
Diclofenac consumption during the first four days, mg, mean 324.1 340.4 0.57
Alertness OAA/S score 6 h after surgery, mean 5.0 4.4 <0.001
OAA/S - observer's assessment of alertness/sedation.
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thetic. Furthermore, we used an elastomeric pump,
which enabled a continuous infusion of the local anaes-
thetic. That is probably the reason why only seven pa-
tients (23.1%) in the test group reported pain above a
VAS score of 5.0, whereas in the control group, such
pain levels were reported by thirteen patients (42.9%).
Legeby et al. found that the use of opioids was about
three times higher after the implantation of a tissue ex-
pander compared to other breast surgical procedures
[6]. After the tissue-expander implantation with or with-
out axillary dissection, the consumption of opioids was
12.8 mg and 11.8 mg, whereas after mastectomy or
mastectomy with axillary dissection, the mean consump-
tion of opioids was 3.2 mg and 5.5 mg, respectively [6].
Our patients with standard analgesia after the tissue-
expander implantation needed 5.6 times more opioids
than patients who underwent axillary dissection alone
[14]. Local anaesthetics can reduce consumption of opi-
oids after mastectomy and axillary dissection [11,13,14]
and also after breast augmentation with implants [7].
Our study shows that the use of continuous local anaes-
thesia can effectively reduce opioid consumption. Our
patients treated with a local anaesthetic needed about
three times less opioids than the standard analgesia
group. Subsequently, patients from the local anaesthesia
group experienced nausea less often, thus they had a
lower consumption of metoclopramide than the stand-
ard analgesia group. Furthermore, the use of local anaes-
thetics resulted in less sedated and more alert patients in
the recovery room and 6 h after the operation. The com-
plication rate did not differ between the two groups of
patients. This is in agreement with the reports of other
authors who used local anaesthetics [11-13,18,21,25-30].
Some authors report that local anaesthetics appear to re-
duce the incidence of inflammation [31-33].
There was no difference in pain on the first postopera-
tive day between the study and control group of patients.
It means that local anaesthesia was no longer as effective
as it was on the day of surgery. A possible explanation is
that muscle overstretching caused by a tissue expander
is no longer as painful as it was. Other explanations arethat in some patients the position of the wound catheter
might have changed during movement or that there was
a different perfusion region in the erect, prone or supine
position, or that continuous infusion was flawed because
of the wound drainage. Unfortunately, in our study we
did not test a rescue bolus-injection of levobupivacaine
in the case of severe pain. However, we have good ex-
perience with application of a rescue bolus of levobupi-
vacaine in patients with neuropathic pain after axillary
lymphadenectomy. Many times we have observed that
injection of a bolus of 15 mL of 0.25% levobupivacaine
into a drain and clamping of wound drainage inhibited
neuropathic pain for a couple of hours.
Memory of severe postoperative pain is the most im-
portant risk factor for the development of chronic pain
[34]. Patients who were treated with patient-controlled
analgesia had three times less chronic pain than the
traditionally nurse-administered patients [6]. The results
of our study support this observation. Only 17% of pa-
tients treated with a local anaesthetic experienced
chronic pain. This is significantly less than in the stand-
ard analgesia group of patients, of whom 50% suffered
chronic pain. The proportion of patients treated with ax-
illary lymphadenectomy, chemotherapy, hormone ther-
apy and/or irradiation was similar in both study arms.
Hence, we think that inadequately treated acute pain
had an impact on the frequency of chronic pain in the
standard analgesia group.
Conclusions
Our current prospective randomized study shows that a
continuous local anaesthetic infusion with the use of anal-
gesic catheters inserted into the surgical wound after pri-
mary breast reconstruction with a tissue expander reduces
acute pain immediately after the surgical procedure and
also on the operative day. Because of that, it represents an
effective postoperative pain treatment without side effects.
It enables lower opioid consumption in the first 24 h after
the surgical procedure, higher alertness and less nausea.
We observed that patients treated with a local anaesthetic
experienced a lower frequency of chronic pain compared
to patients treated with standard analgesia.
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